Q&A: Novartis’ Eric Hughes on transplantationWith approximately 3.2 million people worldwide living with end-stage renal disease, there is immense pressure on healthcare systems Share XQ&A: Novartis’ Eric Hughes on transplantationhttps://pharmaphorum.com/r-d/views-analysis-r-d/novartis-eric-hughes-transplantation/
Conatus axes staff after latest failure of Novartis-partnered NASH drugConatus has said it will have to cut around 40% of its workforce and jettison some pipeline projects Share XConatus axes staff after latest failure of Novartis-partnered NASH drughttps://pharmaphorum.com/news/conatus-axes-staff-after-latest-nash-trial-failure/
Gilead NASH drug fails late stage trialGilead’s top late-stage drug selonsertib, for patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH), has failed a Share XGilead NASH drug fails late stage trialhttps://pharmaphorum.com/news/gilead-nash-drug-fails-late-stage-trial/
Promethera looks to Asia with €10m investmentBelgium-based liver disease specialists Promethera Biosciences have received a leg-up for the Asian market in the form of Share XPromethera looks to Asia with €10m investmenthttps://pharmaphorum.com/news/promethera-looks-to-asia-with-e10m-investment/
Novartis muscles into NASH fatty liver diseaseCompany’s Eric Hughes on what it takes to be leader in NASH – and what can be learnt from hepatitis C. Share XNovartis muscles into NASH fatty liver diseasehttps://pharmaphorum.com/views-and-analysis/novartis-muscles-nash-fatty-liver-disease/